Strategic partnership agreement with Yourgene Health plc


Collaboration to broaden testing capabilities through EKF’s accredited US laboratory beyond COVID-19


EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, has signed a strategic partnership agreement with Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, whereby EKF will offer a non-invasive prenatal test (“NIPT”) service to the US market based on Yourgene’s proprietary Flex technology, using EKF’s accredited US laboratory to process returned test samples. Over time, EKF and Yourgene intend to provide further tests including in oncology, for which Yourgene has additional tests. The agreement is for an initial 5-year period.


EKF’s facilities are those of Advanced Diagnostic Laboratory LLC (“ADL Health”), a recently acquired Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high complexity testing. ADL Health has the in-house testing capabilities to broaden its diagnostics offering from its current range of rapid and accurate COVID-19 testing services into the expanding market of NIPT, amongst other areas. This partnership with Yourgene enables EKF to follow its strategy to grow its CLIA laboratory business beyond COVID. 


As part of the agreement, EKF will purchase state-of-the-art next generation sequencing (“NGS”) technology (“Illumina NextSeq 550”) and Yourgene’s proprietary technology, to enable ADL to build NIPT screening services for a wide range of clinical conditions across reproductive health (including Down’s Syndrome and other genetic disorders). It also provides the opportunity to use NGS technology independently to extend EKF’s testing capabilities into other areas such as cardio-vascular disease testing (designed to determine the genetic predisposition towards cardiomyopathy, hypercholestermia, and other risk factors), hereditary cancer risk, genetic predisposition for Alzheimer’s disease, Parkinson’s disease and dementia.


The adoption for NIPT in the US has accelerated with recent guidelines issued from American College of Obstetricians and Gynaecologists (“ACOG”) recommending NIPT to be made available to all pregnant women1. As part of the agreement, Yourgene will provide ADL Health with access to YGEN’s proprietary reagents and NGS analysis software as part of a technology transfer agreement to enable ADL Health to build a rapid turnaround NIPT service for the US market. Currently, a majority of US NIPT samples are sent to large central testing laboratories, which are costly and experience lengthy lead times. In contrast, the new ADL NIPT service will offer rapid turnaround times as the NIPT workflow can be performed in as little as 48 hours, enabling a competitive response and allowing both EKF and Yourgene to gain traction in this large growing market. According to third party forecasts, the US NIPT market is expected to reach a valuation of USD 2.5 Billion by 20282.


Within the collaboration Yourgene will also provide ADL Health a range of YGEN’s additional PCR portfolio for screening Cystic Fibrosis, rapid aneuploidy assay and DPYD (chemotherapy toxicity) tests, creating a wider range of products for use in reproductive health and oncology.


Mike Salter, Chief Executive Officer, commented: “We are extremely pleased to have formed this partnership with Yourgene, allowing EKF to offer NIPT and oncology tests as part of its proposed strategy of expanding its CLIA laboratory testing portfolio beyond COVID-19 assays. We are thrilled to be growing our reach further within the largest healthcare market in the world and look forward to working with Yourgene going forward.”


Lyn Rees, Chief Executive Officer of Yourgene, commented: “We are thrilled to have entered into this collaboration with EKF and ADL Health, a well-established group in the US with a large clinical network of customers positioned to increase uptake of the tests. This partnership is testament to the strength of our technical capabilities and accelerates our US growth plans to broaden our portfolio in the region with strategic partners. I am excited to be working with EKF and this partnership is a great platform for growth within the largest healthcare market in the world.” 


  1. ACOG Practice Bulletin No. 226. American College of Obstetricians and Gynecologists. Obstet Gynecol 2020;136:e48–69), summarised at


For further information please contact:


EKF Diagnostics Holdings plc

Christopher Mills, Non-executive Chairman

Tel: +44 (0)29 2071 0570

Mike Salter, CEO


Richard Evans, FD & COO




Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Tom Salvesen




Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or  

Paul McManus / Lianne Cawthorne

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 



Back to ListingPreviousNext